Drugs / AR-13503
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03835884 | Jun 2019 → May 2022 | diabetic macular edema, wet macular degeneration | Aerie Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-13503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03835884 ↗ |
| Route | Intravitreal | “administered as an intravitreal implant” NCT03835884 ↗ |